Collaboration Agreements (Tables)

12 Months Ended

Dec. 28, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Collaborative Revenues Under Collaboration Agreement

Collaboration revenues under the collaboration agreement with Ipsen were as follows (in thousands):



	Year Ended December 31,
	2018		2017		2016
Ipsen collaboration revenues	$	182,879	$	69,792	$	33,252

Collaboration revenues under the collaboration agreement with Merck were as follows (in thousands):



	Year Ended December 31,
	2018		2017		2016
Merck collaboration revenues	$	—	$	—	$	5,000

Profits and losses on U.S. commercialization and Royalty revenues on ex-U.S. sales under the collaboration agreement with Genentech were as follows (in thousands):



	Year Ended December 31,
	2018		2017			2016
Profits and losses on U.S. commercialization	$	8,084	$	(2,140	)	$	8,771
Royalty revenues on ex-U.S. sales	$	5,564	$	6,398		$	2,827

Collaboration revenues under the ROR collaboration agreement with BMS were as follows (in thousands):



	Year Ended December 31,
	2018		2017		2016
BMS collaboration revenues	$	—	$	12,500	$	—

Collaboration revenues under the collaboration agreement with Daiichi Sankyo were as follows (in thousands):



	Year Ended December 31,
	2018		2017		2016
Daiichi Sankyo collaboration revenues	$	20,000	$	—	$	15,000

Collaboration revenues under the collaboration agreement with Takeda were as follows (in thousands):



	Year Ended December 31,
	2018		2017
Takeda collaboration revenues	$	18,020	$	14,779

Such royalties were as follows (in thousands):



	Year Ended December 31,
	2018		2017		2016
Royalties accruing to GSK	$	23,950	$	12,413	$	4,334